Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

Lipocine (LPCN) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 36 quarters since 2012. Compare with LPCN stock chart to see long term trends.

LPCN stock compared to

LPCN Income Statement

Revenue, Net:null
Research & Development Expense:2479870
Total Operating Expenses:4801674
Operating Income:-7831827
Income Taxes:0
Net Income:-4511276
Earnings Per Share, Basic:-0.04
Shares Outstanding, Basic Avg:55688085

LPCN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1157
Net Cash from Operations:-3684029
Net Cash from Financing Activities:4555225
Net Cash from Investing Activities:5408000
Net Change in Cash & Equivalents:6279196

LPCN Balance Sheet

Cash and Cash Equivalents:24217382
Total Current Assets:25329023
Property, Plant & Equipment, Net:null
Total Assets:25352776
Accounts Payable:1597220
Total Short-Term Liabilities:6583731
Long Term Debt, Non-Current Portion:2257075
Total Liabilities:10010857

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
2,957,883 sh
1,853,579 sh
168%
$4,171
$2,780
Blackrock Inc.
1,610,701 sh
887,601 sh
123%
$2,271
$1,360
Ameriprise Financial Inc
786,000 sh
-2,500 sh
0%
$1,108
$114
Sabby Management, LLC
443,469 sh
429,017 sh
2969%
$625
$607
Mercer Global Advisors Inc /Adv
241,210 sh
-30,799 sh
-11%
$340
-$3
Northern Trust Corp
88,480 sh
31,231 sh
55%
$125
$53
Price T Rowe Associates Inc /Md/
26,364 sh
26,364 sh
NEW
$37
$37
Credit Suisse Ag/
12,001 sh
12,001 sh
NEW
$17
$17
Morgan Stanley
5,050 sh
3,550 sh
237%
$7
$5
Royal Bank Of Canada
2,000 sh
2,000 sh
NEW
$3
$3
Bank Of America Corp /De/
1,000 sh
 
$1
Renaissance Technologies LLC
0 sh
-316,100 sh
-100%
$0
-$398
Goldman Sachs Group Inc
0 sh
-20,851 sh
-100%
$0
-$26
Proequities, Inc.
0 sh
 
$0

Data imported from Lipocine Inc SEC filings. Check original filings before making any investment decision.